RxDoctor Payments Data

Antonio Rios, MD

Internal Medicine · Gainesville, GANPI 1629061916

Payments from drug & device makers

$765in general payments, 2019–2025

Across 14 payments — averaging $54.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$315
  • Novo Nordisk$145
  • AstraZeneca$126
  • AbbVie$96
  • GSK$29
  • Abbott$22
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$765100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen3$315
Novo Nordisk3$145
AstraZeneca1$126
AbbVie2$96
GSK2$29
Abbott1$22
Lilly USA, LLC1$18
Globus Medical1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$765 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$73,175
Medicare patients
157
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin148$180,855
RybelsusSemaglutide43$84,787
OzempicSemaglutide67$71,106
EliquisApixaban67$66,259
JanuviaSitagliptin Phosphate49$51,519
LinzessLinaclotide48$45,621
TrulicityDulaglutide36$35,576
Breo ElliptaFluticasone/Vilanterol58$30,448
XareltoRivaroxaban18$25,842
FarxigaDapagliflozin Propanediol22$22,057
Tresiba Flextouch U-100Insulin Degludec26$15,189
Repatha SureclickEvolocumab13$13,667
Novolog FlexpenInsulin Aspart39$10,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,071
ShingrixVaricella-Zoster Ge/As01b/Pf31$6,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$145$155,893110 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix, Arexvy, Anoro Ellipta$29$57,711136 claims
AbbVieLinzess, Synthroid$96$47,82169 claims
Lilly USA, LLCTrulicity$18$35,57636 claims
AstraZenecaFarxiga$126$22,05722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →